[go: up one dir, main page]

MX2009005651A - Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca. - Google Patents

Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca.

Info

Publication number
MX2009005651A
MX2009005651A MX2009005651A MX2009005651A MX2009005651A MX 2009005651 A MX2009005651 A MX 2009005651A MX 2009005651 A MX2009005651 A MX 2009005651A MX 2009005651 A MX2009005651 A MX 2009005651A MX 2009005651 A MX2009005651 A MX 2009005651A
Authority
MX
Mexico
Prior art keywords
cardiac arrhythmia
risk management
genetic markers
markers
assessing
Prior art date
Application number
MX2009005651A
Other languages
English (en)
Inventor
Anna Helgadottir
Daniel Gudbjartsson
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IS8576A external-priority patent/IS8576A/is
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of MX2009005651A publication Critical patent/MX2009005651A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Ecology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La invención se refiere a un procedimiento y a los métodos para determinar una susceptibilidad a la arritmia cardiaca, incluyendo la Fibrilación auricular, Aleteo Atrial y Apoplejía, mediante la evaluación de la presencia o ausencia de los alelos en marcadores polimórficos que están asociados con la Fibrilación auricular, Aleteo Auricular y Apoplejía. La invención se refiere además a los kits que abarcan los reactivos para evaluar tales marcadores, y los métodos de diagnóstico, usos y procedimientos para utilizar tales marcadores de susceptibilidad.
MX2009005651A 2006-12-05 2007-12-05 Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca. MX2009005651A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IS8576A IS8576A (is) 2006-12-05 2006-12-05 Genetic susceptibility variants of atrial fibrillation and stroke
IS8658 2007-06-29
PCT/IS2007/000021 WO2008068780A2 (en) 2006-12-05 2007-12-05 Genetic markers for risk management of cardiac arrhythmia

Publications (1)

Publication Number Publication Date
MX2009005651A true MX2009005651A (es) 2009-06-08

Family

ID=39133840

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005651A MX2009005651A (es) 2006-12-05 2007-12-05 Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca.

Country Status (15)

Country Link
US (2) US8637244B2 (es)
EP (1) EP2121979B1 (es)
JP (1) JP5646174B2 (es)
KR (2) KR101582321B1 (es)
AU (1) AU2007330306B2 (es)
BR (1) BRPI0720116B8 (es)
CA (1) CA2673123C (es)
DK (1) DK2121979T3 (es)
EA (1) EA017529B1 (es)
IL (1) IL199049A (es)
MX (1) MX2009005651A (es)
NO (1) NO20092530L (es)
NZ (1) NZ577805A (es)
SG (1) SG177185A1 (es)
WO (1) WO2008068780A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673123C (en) * 2006-12-05 2019-04-30 Decode Genetics Ehf. Genetic markers for risk management of cardiac arrhythmia
AU2009339152B2 (en) * 2009-01-30 2015-11-19 Bio-Rad Europe Gmbh Method for the in vitro diagnosis of stroke
EP2414543B1 (en) * 2009-04-03 2016-10-12 Decode Genetics EHF Genetic markers for risk management of atrial fibrillation and stroke
WO2011042920A1 (en) * 2009-10-07 2011-04-14 Decode Genetics Ehf Genetic variants indicative of vascular conditions
AU2011227108A1 (en) * 2010-03-19 2012-10-11 Cardiodx, Inc. Determining susceptibility to a sudden cardiac event
WO2011153428A1 (en) * 2010-06-03 2011-12-08 Medtronic, Inc. System and method for assessing a likelihood of a patient to experience a future cardiac arrhythmia using dynamic changes in a biological parameter
WO2012000119A1 (en) * 2010-07-02 2012-01-05 Prognomix Inc. A method of determining a predisposition to atrial fibrillation in a subject
US8715646B2 (en) * 2010-07-29 2014-05-06 The Board Of Trustees Of The University Of Illinois Methods of determining need for anti-coagulation therapy
KR101230088B1 (ko) * 2010-11-24 2013-02-05 연세대학교 산학협력단 심방세동의 예후 예측 방법
KR101331787B1 (ko) * 2011-10-04 2013-11-21 한국과학기술연구원 심장 부정맥 진단용 바이오마커 및 이를 이용한 심장 부정맥 진단 방법
EP3088900B1 (en) 2011-10-17 2020-08-12 Roche Diagniostics GmbH Troponin as marker for intermittent atrial fibrillation
US20140364334A1 (en) * 2011-12-21 2014-12-11 Nuclea Biotechnologies, Inc. Congestive heart failure biomarkers
MX375673B (es) 2012-04-02 2025-03-06 Berg Llc Ensayos basados en interrogatorios celulares y usos de los mismos.
KR101462006B1 (ko) * 2013-07-23 2014-11-18 한국과학기술연구원 심장 부정맥 진단용 바이오마커 및 이를 이용한 심장 부정맥 진단 방법
WO2015026423A1 (en) 2013-08-20 2015-02-26 Infusion Medical, Inc. Syringe fill system and method
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
AU2015314956A1 (en) 2014-09-11 2017-04-06 Berg Llc Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data
US10678367B1 (en) * 2015-09-11 2020-06-09 Apple Inc. Compressive touch sensing
CA2999890A1 (en) * 2015-09-24 2017-03-30 Caris Science, Inc. Method, apparatus, and computer program product for analyzing biological data
KR101883657B1 (ko) * 2016-05-13 2018-07-31 연세대학교 산학협력단 단일염기다형성에 의한 심방세동의 예측 또는 진단에 관한 정보 제공 방법
RU2657942C1 (ru) * 2017-07-25 2018-06-18 Федеральное государственное бюджетное образовательное учреждение высшего образования Читинская государственная медицинская академия Министерства здравоохранения российской федерации Способ прогнозирования риска развития фибрилляции предсердий у женщин с ишемической болезнью сердца
RU2664430C1 (ru) * 2017-12-14 2018-08-17 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития инсульта у мужчин на основе генетического тестирования
CN109324189B (zh) * 2018-08-15 2021-10-01 泰达国际心血管病医院 多蛋白组合物的应用及先天性心脏病筛查试剂盒
KR20210072013A (ko) 2018-11-02 2021-06-16 (주)셀트리온 비후성 심근증 치료용 약학 조성물
US12117453B2 (en) 2018-12-07 2024-10-15 Washington University Predicting patient response to sodium channel blockers
JP7165100B2 (ja) * 2019-04-23 2022-11-02 ジェネシスヘルスケア株式会社 心房細動及び／又は心室細動のリスクを判定する方法
WO2021118796A1 (en) * 2019-12-13 2021-06-17 Ischemia Care Llc Biomarkers for the diagnosis of atrial fibrillation cause of stroke
KR102250719B1 (ko) * 2020-01-07 2021-05-11 고려대학교 산학협력단 발작성 심방세동 환자의 재발 위험도 예측을 위한 바이오 마커
US20230332236A1 (en) * 2020-10-08 2023-10-19 Ischemia Care Llc Method for diagnosing stroke utilizing gene expression signatures
IL301112A (en) * 2020-10-20 2023-05-01 Genetic Tech Limited Methods of assessing risk of developing a disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
ATE98300T1 (de) * 1983-01-10 1993-12-15 Gen Probe Inc Verfahren zum aufspueren, identifizieren und quantifizieren von organismen und viren.
US5288611A (en) * 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5288644A (en) * 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DE69133293T2 (de) 1990-12-06 2004-05-27 Affymetrix, Inc., Santa Clara Verfahren und Reagenzien für immobilisierten Polymersynthese in sehr grossem Masstab
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
WO2004028341A2 (en) * 2001-03-19 2004-04-08 Decode Genetics Ehf. Susceptibility gene for human stroke; methods of treatment
CA2673123C (en) * 2006-12-05 2019-04-30 Decode Genetics Ehf. Genetic markers for risk management of cardiac arrhythmia

Also Published As

Publication number Publication date
JP5646174B2 (ja) 2014-12-24
JP2010511404A (ja) 2010-04-15
EP2121979B1 (en) 2017-07-12
BRPI0720116B8 (pt) 2021-07-27
EP2121979A2 (en) 2009-11-25
US20140227693A1 (en) 2014-08-14
CA2673123A1 (en) 2008-06-12
CA2673123C (en) 2019-04-30
AU2007330306B2 (en) 2013-10-24
NZ577805A (en) 2012-09-28
US20090325163A1 (en) 2009-12-31
KR20150113216A (ko) 2015-10-07
WO2008068780A3 (en) 2008-10-09
NO20092530L (no) 2009-09-03
SG177185A1 (en) 2012-01-30
KR20090087494A (ko) 2009-08-17
AU2007330306A1 (en) 2008-06-12
DK2121979T3 (en) 2017-09-25
KR101582321B1 (ko) 2016-01-05
US8637244B2 (en) 2014-01-28
IL199049A (en) 2014-09-30
EA017529B1 (ru) 2013-01-30
WO2008068780A2 (en) 2008-06-12
BRPI0720116A2 (pt) 2014-01-14
BRPI0720116B1 (pt) 2018-05-02
EA200970578A1 (ru) 2009-12-30

Similar Documents

Publication Publication Date Title
MX2009005651A (es) Marcadores geneticos para el manejo de riesgo de la arritmia cardiaca.
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
GB2477868A (en) Methods and systems for incorporating multiple environmental and genetic risk factors
EP2663656A1 (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
NZ589863A (en) Genetic markers for weight management and methods of use thereof
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
NZ595918A (en) Genetic markers for risk management of atrial fibrillation and stroke
NZ593628A (en) Genetic variants useful for risk assessment of thyroid cancer using rs944289
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
NZ590833A (en) Genetic variants for breast cancer risk assessment
WO2010036960A3 (en) Methods for treating, diagnosing, and monitoring lupus
WO2007028161A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
NZ590893A (en) Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment
NZ598009A (en) Genetic markers associated with risk of diabetes mellitus
WO2008144761A3 (en) Methods and compositions for identifying and treating lupus
WO2009062166A3 (en) Dna microarray based identification and mapping of balanced translocation breakpoints
WO2010103292A3 (en) A genotyping tool for improving the prognostic and clinical management of ms patients
WO2010037859A3 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2008137121A3 (en) Methods for detecting an increased risk for coronary heart disease
WO2013132074A3 (en) A genotyping test for assessing risk of autism
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
WO2009065511A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration